CONCERN 2: THE SECOND GENERATION of CONCERN

Originally founded in 1981 by a small group of friends concerned about saving lives from the tragic disease of cancer, Concern 2 has a rich history and continues to make an impact on cancer immunology research worldwide. At its inception, members of Concern 2 decided the organization’s focus would be to raise money and awareness about one of the most devastating forms of cancer – children’s cancers. Almost thirty years later, a small group of concerned young adults has banded together again to revitalize Concern 2 as the third generation of the Concern Foundation.

With our members ranging from those who have been involved in Concern since childhood, to young adults looking to get involved in a new group passionate for its cause, Concern 2 is one of the fastest growing and most successful charitable organizations in the greater Los Angeles area. Since 1981, the accomplishments of Concern 2 have been recognized worldwide. Concern 2 is responsible for providing “seed” money to establish Los Angeles’ first brain tumor laboratory for young people at Children’s Hospital of Los Angeles. Additionally, this pivotal organization has funded the first ever cancer research exchange program between Children’s Hospital Los Angeles and the Institute for Pediatric Oncology, Cancer Research Center in Moscow, Russia. 

The “younger adult” organization’s passion and drive remain as strong as it was when is began over thirty years ago. Concern 2 continues its strong relationship with such established and pivotal organizations as Children’s Hospital Los Angeles and the AYA@USC to change the landscape of immunology research of childhood and young adult cancers. Concern 2 leads the effort of raising funds and awareness as one of the official selected charities of the Los Angeles Marathon.  Nearly 150 Concern & Concern 2 members have participated in the LA Marathon & 5k as well as the New York City marathon the past five years and have raised over $730,000 for cancer research focused on pediatric and young adult cancers.